Louise M. O’BRien

Louise M. O’BRien

Auto-generated profile, based on publicly available information

Louise M. O’BRien

Cancer Research UK Cambridge Institute, University of Cambridge

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJoachim Hanna
Joachim Hanna
FBFlavio Beke
Flavio Beke
LOLouise M. O’brien
Louise M. O’brien
CKChrysa Kapeni
Chrysa Kapeni
HCHung-Chang Chen
Hung-Chang Chen
MRMaike de la Roche
Maike de la Roche
Th17 cells are key drivers of autoimmune disease. However, the signaling pathways regulating Th17 polarization are poorly understood. Hedgehog signaling regulates cell fate decisions during embryogenesis and adult tissue patterning. Here we find that cell-autonomous Hedgehog signaling, independent of exogenous ligands, selectively drives the polarization of Th17 cells but not other T helper cell subsets. We show that endogenous Hedgehog ligand, Ihh, signals to activate both canonical and non-canonical Hedgehog pathways through Gli3 and AMPK. We demonstrate that Hedgehog pathway inhibition with either the clinically-approved small molecule inhibitor vismodegib or genetic ablation of Ihh in CD4+ T cells greatly diminishes disease severity in two mouse models of intestinal inflammation. We confirm that Hedgehog pathway expression is upregulated in tissue from human ulcerative colitis patients and correlates with Th17 marker expression. This work implicates Hedgehog signaling in Th17 polarization and intestinal immunopathology and indicates the potential therapeutic use of Hedgehog inhibitors in the treatment of inflammatory bowel disease.

11 July 2025 in Science Immunology
Verified
Journal Article
Closed access
CKChrysa Kapeni
Chrysa Kapeni
LOLouise O’bRien
Louise O’bRien
DSDilyara Sabirova
Dilyara Sabirova
OCOliver Cast
Oliver Cast
VCValentina Carbonaro
Valentina Carbonaro
MRMaike de la Roche
Maike de la Roche
The Hedgehog (Hh) signaling pathway is aberrantly regulated in cancer. Hh inhibitors are successful in treating basal cell carcinoma (BCC) and Sonic Hedgehog–driven medulloblastoma but have largely failed in clinical trials of other solid cancers. We show that Hh inhibitor treatment specifically diminishes CD8 T cell migration into the tumor microenvironment, both in murine cancer models and resected BCCs from patients treated with the Smoothened (Smo) inhibitor vismodegib. Using small-molecule antagonists and genetic knockout models of key Hh signaling components, we demonstrate that the migration defect is mediated exclusively by the signal transducer Smo and not Hh ligands or Gli transcription factors. Smo acts noncanonically as a G protein–coupled receptor to regulate the migration of murine and human CD8 T cells via RhoA. Our data establish a link between Hh inhibition in vivo and the antitumor immune response and provide the basis for improved Hh targeting approaches for patients with cancer.

8 June 2026 in EMBO Reports
Verified
Journal Article
Open access
PDF file
FBFlavio Beke
Flavio Beke
JHJoachim Hanna
Joachim Hanna
CKChrysa Kapeni
Chrysa Kapeni
VCValentina Carbonaro
Valentina Carbonaro
NMNico Mueller
Nico Mueller
MRMaike de la Roche
Maike de la Roche
Cytotoxic CD8 + T lymphocytes (CTLs) efficiently eliminate infected and cancerous cells throughout the body. T cell receptor (TCR)-induced Hedgehog signalling contributes to CTL-mediated killing, but how the pathway is activated downstream of the TCR is unknown. Here, we show that extracellular calcium (Ca 2+ ) flux through L-type voltage-gated Ca 2+ (Ca v 1) channels at the plasma membrane downstream of the TCR drives induction of the Hedgehog transcription factor Gli1, which is important for CTL killing in vitro and in vivo. This previously unknown non-canonical Hedgehog pathway is independent of canonical signalling and represents a primary mechanism of Gli1 induction in naive CD8 + T cells, whereas CTLs can also activate Gli1 via MAPK. We further show that Ca v 1 channel-controlled Gli1 induction is functionally important for CTL killing in mice and humans and other cytotoxic lymphocytes. Notably, killing capacity can be amplified using a small molecule Ca v 1 agonist or by overexpressing a gain-of-function Ca v 1 subunit. These findings suggest a strategy to improve cytotoxic lymphocyte function in the clinic, including in CAR T cell therapy.

2 August 2026
Verified
Book Chapter
Closed access
PDF file
LOLouise M. O’BRien
Louise M. O’BRien
JJJulia Jones
Julia Jones
RCRita Carreira
Rita Carreira
CBCara Brodie
Cara Brodie
ESElsa Santos
Elsa Santos
MRMaike de la Roche
Maike de la Roche

1 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJoachim Hanna
Joachim Hanna
CKChrysa Kapeni
Chrysa Kapeni
LOLouise O’brien
Louise O’brien
VCValentina Carbonaro
Valentina Carbonaro
FBFlavio Beke
Flavio Beke
MRMaike de la Roche
Maike de la Roche
Cytotoxic CD8 + T lymphocytes (CTLs) are critical to the immune response against intracellular pathogens and cancer and act by eliminating infected and malignant cells through targeted secretion of cytotoxic granules. Hedgehog (Hh) signaling has been shown to be critical for CTL killing. Interestingly, Hh signaling in CD8 + T cells is not induced by extracellular Hh ligands but is initiated upon T cell receptor (TCR) engagement. How the TCR induces the Hh pathway independently of extracellular Hh ligands is unknown. Here we show that the Hh transcription factor Gli1 is essential for efficient CTL function and is induced downstream of the TCR by an extracellular Ca 2+ influx selectively controlled by L-type voltage gated Ca 2+ channels localized at the plasma membrane. We demonstrate that this novel mode of Hh signaling induction is independent of the canonical Hh pathway and represents the primary mechanism of Gli1 induction in naïve CD8 + T cells, while CTLs can also activate Gli1 via MAP Kinase signaling. Importantly, we show that this L-type voltage gated Ca 2+ channel-controlled Gli1 induction is functionally required for CTL killing in mice and humans. Gli inhibitors are currently in clinical trials against various cancers and our observations indicate that they likely inhibit the anti-tumor response. Significance statement: Cytotoxic CD8 + T cells (CTLs) kill infected and malignant cells by targeted secretion of cytotoxic granules. Hedgehog signaling is critical for effective CTL killing and is activated by the T cell receptor (TCR) independently of exogenous Hedgehog ligands. This study shows that Hedgehog transcription factor Gli1 is required for CTL killing and identifies L-type voltage gated Ca 2+ channels (Cav1) as essential regulators of CTL killing in mouse and human, by virtue of their ability to activate Gli1 downstream of the TCR. This Cav1-Gli1 axis operates independently of canonical Hedgehog signaling. Our work suggests that caution is required when using Gli inhibitors, currently in trials as anti-cancer therapeutics, since they may dampen the anti-tumor response.